369 related articles for article (PubMed ID: 2896329)
1. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Mar; 2(3):273-7. PubMed ID: 2451200
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
4. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
[TBL] [Abstract][Full Text] [Related]
8. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
9. Influence of antibody isotype on passive serotherapy of lymphoma.
Denkers EY; Badger CC; Ledbetter JA; Bernstein ID
J Immunol; 1985 Sep; 135(3):2183-6. PubMed ID: 2862210
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O
Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016
[TBL] [Abstract][Full Text] [Related]
11. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.
Steplewski Z; Lubeck MD; Scholz D; Loibner H; McDonald Smith J; Koprowski H
In Vivo; 1991; 5(2):79-83. PubMed ID: 1768791
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R
Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152
[TBL] [Abstract][Full Text] [Related]
14. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
Kaminski MS; Kitamura K; Maloney DG; Campbell MJ; Levy R
J Immunol; 1986 Feb; 136(3):1123-30. PubMed ID: 3484499
[TBL] [Abstract][Full Text] [Related]
15. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI
Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151
[TBL] [Abstract][Full Text] [Related]
16. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
17. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
18. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
Yu D; Shi D; Scanlon M; Hung MC
Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
